"10.1371_journal.pone.0085211","plos one","2014-01-09T00:00:00Z","Maria Fiorentino; Myron M Levine; Marcelo B Sztein; Alessio Fasano","Mucosal Immunology and Biology Research Center, Massachusetts General Hospital, Charlestown, Massachusetts, United States of America; Center for Vaccine Development and the Departments of Pediatrics and Medicine, University of Maryland School of Medicine, Baltimore, Maryland, United States of America","Conceived and designed the experiments: MF AF. Performed the experiments: MF. Analyzed the data: MF AF MBS. Wrote the paper: MF AF MBS MML.","Dr. M. M. Levine is co-inventor in patents for attenuated Shigella vaccines (gua mutants of Shigella spp. and vaccines containing the same. Patent US 5,783,196; Isolated DNA molecule encoding SHET1 of Shigella flexneri 2a and mutant Shigella flexneri 2a. Patent US 5,589,380). However, heretofore no company has licensed this technology and therefore there is no commercial “product” in development. The patent exists on paper only. Dr. A. F. is co-Founder and stock holder of Alba Therapeutics, a company working on treatments for celiac disease. No relation with the content of this manuscript. The remaining authors declare no conflicting financial interests. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.","2014","01","Maria Fiorentino","MF",4,TRUE,2,1,3,4,TRUE,TRUE,FALSE,0,NA,FALSE
